Выбор редакции

More on ARIAD Pharmaceuticals ([[ARIA]] -9.4%): shares take a hit today after its Q2 misses estimates. Restructuring charges related to its agreement with Merck ([[MRK]] -1.7%), as well as a revaluation of the company's warrant liability both dug a deeper-than-anticipated hole into bottom-line margins.

More on ARIAD Pharmaceuticals (ARIA -9.4%): shares take a hit today after its Q2 misses estimates. Restructuring charges related to its agreement with Merck (MRK -1.7%), as well as a revaluation of the company's warrant liability both dug a deeper-than-anticipated hole into bottom-line margins. Post your comment!
НОВОСТИ ПО ТЕМЕ